Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 11, 2026 · Material agreement · Item 3.02 · Investor press release · +1 more
Edesa Biotech, Inc.
9
Material agreement
Jun 11, 2026
| Item 1.01 | Entered a material definitive agreement |
| Item 3.02 | Item 3.02 |
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 9.01 | Financial statements and exhibits |
Edesa Biotech, Inc. filed this to report entering into or terminating a material contract that could affect operations, partnerships, or future hiring.
5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $3.
This filing reports Item 1.01 (entered a material definitive agreement). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
Edesa Biotech, Inc. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
